MRCP FRCPath (UK)
CONSULTANT HAEMATOLOGIST
Milton Keynes, Bedford, Buckingham, Northampton, Luton
Phone  |  01908 995 814
  Publications
  home
 
 Home > Publications
  Get in touch
For private appointments
and enquiries, please contact:
   
Phone 01908 995 814
Email moez.dungarwalla@mkhospital.nhs.uk
bottom
Private clinic hours:
 
BMI Saxon Clinic
Milton Keynes, MK6 5LR
Friday, 6pm - 9pm
 
Linford Wood Medical Centre
Milton Keynes, MK14 6LS
Monday, 5pm - 7pm
Tuesday, 5pm - 7pm
bottom
 
  Specialities
Leukaemia
Lymphoma
Myeloma
Anaemia
Other disorders
Publications

List of recent publications by Dr Moez Dungarwalla, Haematology specialist in Milton Keynes.
 
British Journal of Haematology High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis
M. Dungarwalla, S. Appiah-Cubi,  S. Kulkarni, R. Saso,  et al
British Journal of Haematology, Volume 143, Issue 1, pages 71–74, October 2008
 
Abstract:  In a series of 48 patients with splenic marginal zone lymphoma (SMZL) with circulating villous lymphocytes, we describe the clinical and laboratory features of nine cases that transformed to high-grade B-cell lymphoma. These patients had a significantly greater incidence of ...
Keywords:  splenic marginal zone lymphoma;  transformation;  clinical features;  prognosis
 
 
European Journal of Haematology Prolymphocytic leukaemia of B and T cell subtype: a state of the art paper
M. Dungarwalla, E. Matutes, C. E. Dearden
European Journal of Haematology, Volume 80, Issue 6, pages 469–476, June 2008
 
Abstract:  Prolymphocytic leukaemias of B and T cell subtype are rare diseases. Despite recent advances in immunophenotyping and molecular cytogenetics, leading to a better understanding of the underlying cell biology of the prolymphocytic leukaemias, prognosis for these patients ...
Keywords:  prolymphocytic;  leukaemia;  cell biology;  clinical features;  management
 
 
High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy
M. Dungarwalla, S. Evans, U. Riley, D. Catovsky, C. Riley, E. Matutes.
Haematologica. March 2008
 
Abstract:  The combination of high dose methylprednisolone and rituximab induces superior overall (93%) and complete (14%) response rates compared to high dose methylprednisolone alone (overall 43%, complete remission 0%) in heavily pre-treated chronic lymphocytic leukemia patients with advanced disease...
Keywords:  chronic lymphocytic leukemia;
 
 
Annals of Hematology Cutaneous Mycobacterium chelonae infection in chronic lymphocytic leukaemia
M Dungarwalla, A Field-Smith, C Jameson, U Riley, A Chapman, et al
Haematologica. January 2007
 
Abstract:  We describe 11 patients with severe refractory autoimmune cytopenias treated with
the anti-CD20 mono- clonal antibody rituximab.  Six patients had autoimmune neutropenia
(AIN), two had pure red cell aplasia (PRCA), one had AIN and autoimmune haemolytic ...
Keywords:  Rituximab;   Campath-1H;   Autoimmune neutropenia;   Pure red cell aplasia
 
 
Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology
M. Dungarwalla, J. C. W. Marsh, J. A. Tooze, G. Lucas, W. Ouwehand, et al
ANNALS OF HEMATOLOGY, Volume 86, Number 3, 191-197. March 2007
 
Abstract:  A 67 year old man was diagnosed with chronic lympho- cytic leukaemia (CLL) in 1999. He was also known to have hypogammaglobulinaemia and bronchiectasis. He had been previously treated with 12 cycles of chloram- bucil, 2 cycles of fludarabine ...
Keywords:  chronic lymphocytic leukemia;
 
 
 
  logo logo logo